Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Coherus Oncology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -70.22%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Coherus Oncology's 3-Year ROIIC % or its related term are showing as below:
FRA:8C5's 3-Year ROIIC % is ranked worse than 68.68% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs FRA:8C5: -70.22
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Coherus Oncology 3-Year ROIIC % Related Terms
Coherus Oncology 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Coherus Oncology's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's 3-Year ROIIC % falls into.
Coherus Oncology's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -154.688 (Dec. 2025) - -242.495 (Dec. 2022) )
/
( 59.382 (Dec. 2025) - 167.466 (Dec. 2022) )
=
87.807
/
-108.084
=
-81.24%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Coherus Oncology (FRA:8C5) has a 3-Year ROIIC % of -70.22 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #908 out of 1322 companies in the Biotechnology industry, placing it in the top 68.7%.
Is Coherus Oncology's 3-Year ROIIC % too high?
Coherus Oncology's current 3-Year ROIIC % is -70.22. Based on the distribution chart, Coherus Oncology ranks #908 out of 1322 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's 3-Year ROIIC % compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #908 out of 1322 companies for 3-Year ROIIC %. This places Coherus Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current 3-Year ROIIC % is -70.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €1.24 — trading 90% above its estimated fair value. The current 3-Year ROIIC % is -70.22. Coherus Oncology's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current 3-Year ROIIC % is -70.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.24 is trading 90% above its estimated GF Value™ of €0.65.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
3-Year ROIIC %: -70.22
GF Value™: €0.65 vs. price of €1.24 (90% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
49GF Score
Get the complete analysis for FRA:8C5
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
